A Therapy for Dry Eye Caused by Meibomian Gland Disease
TearCare targets the leading cause of dry eye disease by directly addressing meibomian gland dysfunction.
It works by applying localized heat therapy through a flexible, gentle design that allows patients to blink naturally.
Better Eye Health with Early Intervention
- Better Outcomes TearCare is an early procedural intervention that was proven clinically superior to the leading dry eye prescription therapy by addressing the root cause of MGD.10
- Procedural Intervention With results beginning in one week7 and lasting up to one year.8 TearCare improves gland function for long-term success.8,9
Advancing the Future of MGD
TearCare is a Thermal Adaptive Gland Expression therapy that allows patients to experience an MGD treatment like no other. Smart. Convenient. Long-lasting.10
TearCare treats the root cause of dry eye by improving vital meibomian gland function.
Delivers controlled thermal energy to soften glands obstructions.
Enables the doctor to precisely express glands and improve their natural function.9
- Treats Obstruction
- Proven Superior10
- No Daily Drops
- Treats Obstruction
- Proven Superior
- No Daily Drops
REFERENCES: 1. Market Scope 2021 Ocular Surface Disease Survey. 2. Lemp MA, et al. Cornea. 2012 May; 31(5):472-479. 3. Ayres BD, et al. Clin Ophthalmol. 2023 Dec 18;17:3925-3940. 4. Ayres BD, et al. Clin Ophthalmol. 2024 May 28;18:1525-1534. 5. Blackie CA, et al. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review. Curr Opin Ophthalmol. 2015 Jul;26(4):306-13.
First and Only
TearCare is the first and only MGD treatment indicated to improve meibomian gland function in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD).
- Early intervention Matters
- MGD starts in an asymptomatic stage12
- Gland dropout is irreversible9,18
- Proven Earlier Intervention
- Unsurpassed improvement compared to leading Rx brand in TBUT and MG function10
- Equal to the leading Rx brand in all symptoms while minimizing the drawbacks of poor compliance10,11
- Twelve peer-reviewed publications demonstrating efficacy and safety
- A Better Patient Experience
- Eliminate the burden of prescription daily drops 11
- Reduction in medication compliance challenges
- Comfortable in-office therapy
- A New Order in Care
- Effective therapy can be started earlier in the disease state
- Proactive intervention superior to the #1 dry eye prescription medication 10
- Act before atrophy
- Comprehensive Therapy
- Comfortable open-eye therapy
- Our expert thermal technology combined with your expert hands
TearCare Reimbursement Just Got Real.
1. Holland, E. J., Loh, J., Bloomenstein, M., Thompson, V., Wirta, D., & Dhamdhere, K. (2022). A Comparison of TearCare and Lipiflow Systems in Reducing Dry Eye Disease Symptoms Associated with Meibomian Gland Disease. Clinical ophthalmology (Auckland, N.Z.), 16, 2861–2871. https://doi.org/10.2147/OPTH.S368319
2. Gupta, P. K., Holland, E. J., Hovanesian, J., Loh, J., Jackson, M. A., Karpecki, P. M., & Dhamdhere, K. (2022). TearCare for the Treatment of Meibomian Gland Dysfunction in Adult Patients With Dry Eye Disease: A Masked Randomized Controlled Trial. Cornea, 41(4), 417–426. doi: https://doi.org/10.1097/ico.0000000000002837
3. Chester T. A Single – center Retrospective Trial of a Blink – assisted Eyelid Device in Treating the Signs and Symptoms of Dry Eye. Optometry and Vision Science. 2021;98(6):605 – 612. doi: https://doi.org/10.1097/opx.0000000000001711
4. Badawi D. (2018). A novel system, TearCare®, for the treatment of the signs and symptoms of dry eye disease. Clinical ophthalmology (Auckland, N.Z.), 12, 683–694. https://doi.org/10.2147/OPTH.S160403
5. Badawi D. TearCare® system extension study: evaluation of the safety, effectiveness, and durability through 12 months of a second TearCare® treatment on subjects with dry eye disease. Clinical Ophthalmology. 2019; Volume 13:189-198. doi: https://doi.org/10.2147/opth.s191588
6. Chester, T., Longo, R., Masseria, C., Riley, P., Patel, C., & Mody, L. (2025). Budget impact analysis (BIA) of the TearCare System for the treatment of meibomian gland dysfunction (MGD)-associated dry eye disease (DED) in the United States (US). Expert Review of Ophthalmology, 20(1), 55–61. https://doi.org/10.1080/17469899.2024.2444930
7. Karpecki, P., Wirta, D., Osmanovic, S., & Dhamdhere, K. (2020). A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCare® System as a Safe and Effective Blink-Assisted Eyelid Device for the Treatment of Dry Eye Disease. Clinical ophthalmology (Auckland, N.Z.), 14, 4551–4559. https://doi.org/10.2147/OPTH.S285953
8. Chester, T., Ferguson, T., & Chester, E. (2023). Localized Heat Treatment for Meibomian Gland Dysfunction: A Single-Center Retrospective Analysis of Efficacy over Time. Optometry and vision science : official publication of the American Academy of Optometry, 100(9), 625–630. https://doi.org/10.1097/OPX.0000000000002053
9. Blackie CA, et al. Treatment for meibomian gland dysfunction and dry eye symptoms with a single-dose vectored thermal pulsation: a review. Curr Opin Ophthalmol. 2015 Jul;26(4):306-13.
10. Ayres BD, Bloomenstein MR, Loh J, et al. A Randomized, Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA).Clinical Ophthalmology (Auckland, NZ). 2023;17:3925-3940. https://doi.org/10.2147/OPTH.S442971. At 6 months TearCare was superior to Restasis in improving Tear Breakup Time (TBUT) and multiple measures of meibomian gland function and was non-inferior in Ocular Surface Disease Index (OSDI), and all remaining signs and symptoms.
11. Ayres, B. D., Bloomenstein, M. R., Loh, J., Chester, T., Saenz, B., Echegoyen, J., Kannarr, S. R., Rodriguez, T. C., & Dickerson, J. E., Jr (2024). Improved Signs and Symptoms of Dry Eye Disease for Restasis® Patients Following a Single Tearcare® Treatment: Phase 2 of the SAHARA Study. Clinical ophthalmology (Auckland, N.Z.), 18, 1525–1534. https://doi.org/10.2147/OPTH.S464379
12. Tomlinson A, et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011 Mar 30;52(4):2006-49.
13. Hovanesian J, et al. Durability of the TearCare treatment effect in subjects with dry eye disease: Stage 3 of the Sahara randomized controlled trial. Optom Vis Sci. 2025 Aug 1;102(8):495-504.
14. Liu S, Richards SM, Lo K, Hatton M, Fay A, Sullivan DA. Changes in gene expression in human meibomian gland dysfunction. Investigative Ophthalmology & Visual Science. 2011 Apr;52(5):2727–2740.
15. Finis D, Ackerman P, et al. Evaluation of Meibomian Gland Dysfunction and Local Distribution of Meibomian Gland Atrophy by Non-contact Infrared Meibography. Current Eye Research. 2015;40(10):982–989.
16. Gutgesell VJ, Stern GA, Hood CI. Histopathology of meibomian gland dysfunction. Am J Ophthalmol. 1982 Sep;94(3):383-7
17. Hovanesian J, Ayres BD, Bloomenstein MR, Loh J, Chester T, Saenz B, Echegoyen J, Kannarr SR, Rodriguez TC, Dickerson JE Jr. Durability of the TearCare treatment effect in subjects with dry eye disease: Stage 3 of the Sahara randomized controlled trial. Optom Vis Sci. 2025 Aug 1;102(8):495-504.
18. Yang X, et al. Ocul Surf. 2023;29:497-507